PMC:7261349 / 8617-9498
Annnotations
LitCovid_Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T49 | 22-29 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T50 | 22-29 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
| T51 | 261-268 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T52 | 261-268 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 245 | 69-77 | Species | denotes | patients | Tax:9606 |
| 246 | 144-152 | Species | denotes | Patients | Tax:9606 |
| 247 | 470-478 | Species | denotes | patients | Tax:9606 |
| 248 | 22-29 | Chemical | denotes | heparin | MESH:D006493 |
| 249 | 261-268 | Chemical | denotes | heparin | MESH:D006493 |
| 250 | 56-65 | Disease | denotes | mortality | MESH:D003643 |
| 251 | 92-100 | Disease | denotes | Covid-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T31 | 22-29 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
| T32 | 261-268 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T23 | 113-116 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T24 | 441-442 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T25 | 541-545 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T61 | 22-29 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
| T62 | 261-268 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
| T63 | 347-352 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T84 | 0-101 | Sentence | denotes | The administration of heparin was associated with lower mortality in patients admitted with Covid-19. |
| T85 | 102-143 | Sentence | denotes | This study has strengths and limitations. |
| T86 | 144-269 | Sentence | denotes | Patients were not randomized and the difference in outcome may be explained by factors other than the treatment with heparin. |
| T87 | 270-421 | Sentence | denotes | In an effort to control for the severity of disease, or the effects of other drugs, the models were adjusted for clinical markers and other treatments. |
| T88 | 422-611 | Sentence | denotes | The observation of a large number of unselected patients in 17 hospitals, and the analyses run with some variations to test the consistency of the results, are also strengths of this study. |
| T89 | 612-690 | Sentence | denotes | However, residual confounding is always present in all observational research. |
| T90 | 691-881 | Sentence | denotes | For all models the sensitivity analyses described in the methods were used to assess the impact of missing data on the two severity markers, and results were consistent with those presented. |